Van Dis Erik S, Moore Tyler C, Lavender Kerry J, Messer Ronald J, Keppler Oliver T, Verheyen Jens, Dittmer Ulf, Hasenkrug Kim J
Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT 59840, USA.
Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Frankfurt, Germany.
Virology. 2016 Jan 15;488:88-95. doi: 10.1016/j.virol.2015.11.005. Epub 2015 Nov 21.
Amyloid fibrils from semen-derived peptide (SEVI) enhance HIV-1 infectivity in vitro but the ability of SEVI to mediate enhancement of HIV infection in vivo has not been tested. In this study we used immunodeficient mice reconstituted with human immune systems to test for in vivo enhancement of HIV-1 transmission. This mouse model supports mucosal transmission of HIV-1 via the intrarectal route leading to productive infection. In separate experiments with humanized mouse cohorts reconstituted with two different donor immune systems, high dose HIV-1JR-CSF that had been incubated with SEVI amyloid fibrils at physiologically relevant concentrations did not show an increased incidence of infection compared to controls. In addition, SEVI failed to enhance rectal transmission with a reduced concentration of HIV-1. Although we confirmed potent SEVI-mediated enhancement of HIV infectivity in vitro, this model showed no evidence that it plays a role in the much more complex situation of in vivo transmission.
精液衍生肽(SEVI)形成的淀粉样纤维在体外可增强HIV-1的感染性,但尚未测试SEVI在体内介导HIV感染增强的能力。在本研究中,我们使用重建了人类免疫系统的免疫缺陷小鼠来测试HIV-1传播在体内的增强情况。这种小鼠模型支持HIV-1通过直肠内途径进行黏膜传播,从而导致有 productive 感染。在分别用两种不同供体免疫系统重建的人源化小鼠队列进行的实验中,与对照组相比,在生理相关浓度下与SEVI淀粉样纤维孵育的高剂量HIV-1JR-CSF并未显示出感染发生率增加。此外,SEVI未能在HIV-1浓度降低的情况下增强直肠传播。尽管我们在体外证实了SEVI介导的HIV感染性增强作用显著,但该模型没有证据表明它在体内传播这种更为复杂的情况下发挥作用。 (注:“productive infection”直译为“有生产性感染”,结合语境这里可能是指能产生子代病毒等有实际感染效果的情况,具体准确含义需结合更多专业背景知识确定,这里暂保留英文未翻译为更准确的中文表述。)